CN115708409B - 一种化合物的盐、其晶型以及制备方法与应用 - Google Patents

一种化合物的盐、其晶型以及制备方法与应用

Info

Publication number
CN115708409B
CN115708409B CN202080045649.9A CN202080045649A CN115708409B CN 115708409 B CN115708409 B CN 115708409B CN 202080045649 A CN202080045649 A CN 202080045649A CN 115708409 B CN115708409 B CN 115708409B
Authority
CN
China
Prior art keywords
salt
fumarate
fluoro
crystalline form
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080045649.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN115708409A (zh
Inventor
尹磊
姚郑林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan & Lee Pharmaceutical Shandong Co ltd
Original Assignee
Gan & Lee Pharmaceutical Shandong Co ltd
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74040655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115708409(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan & Lee Pharmaceutical Shandong Co ltd, Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan & Lee Pharmaceutical Shandong Co ltd
Publication of CN115708409A publication Critical patent/CN115708409A/zh
Application granted granted Critical
Publication of CN115708409B publication Critical patent/CN115708409B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080045649.9A 2019-06-21 2020-06-22 一种化合物的盐、其晶型以及制备方法与应用 Active CN115708409B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910542355 2019-06-21
CN2019105423556 2019-06-21
PCT/CN2020/097482 WO2020253875A1 (zh) 2019-06-21 2020-06-22 一种化合物的盐、其晶型以及制备方法与应用

Publications (2)

Publication Number Publication Date
CN115708409A CN115708409A (zh) 2023-02-21
CN115708409B true CN115708409B (zh) 2026-08-07

Family

ID=74040655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045649.9A Active CN115708409B (zh) 2019-06-21 2020-06-22 一种化合物的盐、其晶型以及制备方法与应用

Country Status (16)

Country Link
US (1) US20220168302A1 (cg-RX-API-DMAC7.html)
EP (1) EP3988546A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538076A (cg-RX-API-DMAC7.html)
KR (1) KR20220041090A (cg-RX-API-DMAC7.html)
CN (1) CN115708409B (cg-RX-API-DMAC7.html)
AR (1) AR119184A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020296048A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025944A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144546A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003438A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000502A2 (cg-RX-API-DMAC7.html)
IL (1) IL289231A (cg-RX-API-DMAC7.html)
MX (1) MX2022000051A (cg-RX-API-DMAC7.html)
PH (1) PH12021553151A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020253875A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202200964B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113628B (zh) * 2020-08-31 2026-07-17 甘李药业山东有限公司 一种含cdk4/6抑制剂的药物组合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2024208265A1 (zh) * 2023-04-04 2024-10-10 苏州开拓药业股份有限公司 具有刺猬通路拮抗剂活性手性杂环化合物的盐型及其晶型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy;Lei Yin等;European Journal of Medicinal Chemistry;第144卷;1-28 *

Also Published As

Publication number Publication date
WO2020253875A1 (zh) 2020-12-24
EP3988546A4 (en) 2023-05-17
EP3988546A1 (en) 2022-04-27
KR20220041090A (ko) 2022-03-31
JP2022538076A (ja) 2022-08-31
US20220168302A1 (en) 2022-06-02
BR112021025944A2 (pt) 2022-02-08
PH12021553151A1 (en) 2022-07-25
IL289231A (en) 2022-02-01
CN115708409A (zh) 2023-02-21
CA3144546A1 (en) 2020-12-24
CL2021003438A1 (es) 2022-09-30
AR119184A1 (es) 2021-12-01
MX2022000051A (es) 2022-05-24
CO2022000502A2 (es) 2022-01-28
ZA202200964B (en) 2022-08-31
AU2020296048A1 (en) 2022-02-10

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089100

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20260309

Address after: No. 88, Chang'an Road, Chaoyang Street, Economic Development Zone, Linyi City, Shandong Province, 276000

Applicant after: Gan & Lee Pharmaceutical Shandong Co.,Ltd.

Country or region after: China

Address before: 101109 No. 8 Nanfengxi Road, Lixian Town, Tongzhou District, Beijing

Applicant before: GAN & LEE PHARMACEUTICALS

Country or region before: China

GR01 Patent grant